Skip to main content
. Author manuscript; available in PMC: 2019 Aug 14.
Published in final edited form as: Clin Cancer Res. 2012 May 1;18(13):3603–3615. doi: 10.1158/1078-0432.CCR-11-3321

Figure 3: The synergistic inhibition of cell proliferation with combination treatment of MK-2206 and etoposide.

Figure 3:

A: AS, BE2, NGP, and SY5Y cells were treated with etoposide for 48 hrs, cell proliferation was evaluated. B: AS, BE2, NGP, and SY5Y cells were treated with MK-2206 and etoposide either alone or in combination for 48 hrs. The concentrations of each agent spanned the IC50 dose in each cell line. Cell proliferation and combination index were evaluated. C: Caspase 3/7 activity was detected in AS, BE2, NGP, and SY5Y cells treated with MK-2206 (NGP and SY5Y (5μM), AS and BE2 (7.5μM)) and etoposide (AS (20 μg/ml), BE2 (1μg/ml), NGP (0.2 μg/ml) and SY5Y (0.1μg/ml)) either alone or in combination for 24 hrs, Bar, SD. ## P<0.01: MK-2206/etoposide-treated cells versus MK-2206-treated cells; **P<0.01: MK-2206/etoposide-treated cells versus etoposide-treated cells. D: AS, SY5Y, NGP and BE2 cells were pretreated with Z-VAD-fmk (100μM) for 2 hrs followed by treatment of MK-2206 (7.5μM in AS, BE2 cells, 5μM in SY5Y and NGP cells) and etoposide (AS (20μg/ml), SY5Y (0.1μg/ml), NGP (0.1μg/ml), BE2 (1μg/ml)) either alone or in combination. Cell proliferation was evaluated 48 hrs later. Bar, SD, # P<0.05, ## P<0.01: Z-VAD-fmk /etoposide-treated cells versus etoposide-treated cells; **P<0.01: Z-VAD-fmk /etoposide/MK-2206-treated cells versus etoposide/MK-2206-treated cells.